Search
Research
Treatment with inhaled aerosolised ethanol reduces viral load and potentiates macrophage responses in an established influenza mouse modelTreatment options for viral lung infections are currently limited. We aimed to explore the safety and efficacy of inhaled ethanol in an influenza-infection mouse model.
Research
Australian Aboriginal children with otitis media have reduced antibody titers to specific nontypeable Haemophilus influenzae vaccine antigensdecreased serum IgG responses to NTHi outer membrane proteins may contribute to the development of chronic and severe OM in Australian Aboriginal children
Research
Panel 4: Recent advances in understanding the natural history of the otitis media microbiome and its response to environmental pressuresAdvances in understanding bacterial dynamics in the upper airway microbiome are driving development of microbiota-modifying therapies to prevent or treat disease
Research
The Contribution of Geogenic Particulate Matter to Lung Disease in Indigenous ChildrenThe aim of this study was to assess the relationship between dust levels and health in Indigenous children in Western Australia
Research
Safety and immunogenicity of pneumococcal conjugate vaccines in a high-risk population: a randomised controlled trial of PCV in Papua New Guinean infantsInfant vaccination with 3 doses of PCV10 or PCV13 is safe and immunogenic in a highly endemic setting
Research
Production of IgG2 Antibodies to Pneumococcal Polysaccharides After Vaccination of Treated HIV Patients May Be Augmented by IL-7Rα Signaling in ICOS + Circulating T-CellsOur findings suggest that utilization of IL-7 by cTFH cells affects production of IgG2 antibodies to PPV23 antigens in some HIV patients
Research
Combination of clinical symptoms and blood biomarkers can improve discrimination between bacterial or viral community-acquired pneumonia in childrenCombining elevated CRP with the presence or absence of clinical signs/ symptoms differentiates definite bacterial from presumed viral pneumonia better than CRP alone
Research
Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with Pneumococcal Conjugate VaccinePPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses
Research
Role of viral and bacterial pathogens in causing pneumonia among Western Australian children: A case-control study protocolPneumonia is the leading cause of childhood morbidity and mortality globally.
Research
Community immunity: Developing a sensitive and specific SARS-CoV-2 antibody testPeter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group